Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2007

View Archived Issues

Davanat progress updates

TB Alliance supports initiatives in tuberculosis treatment development

Recent patents disclose new agents for treating neurological disorders

Positive phase Ib/II data for PBI-402 in anemia prompts ProMetic to file trial expansion

Actemra improves RA symptoms in latest phase III trial

Oleoyl-estrone discontinued for common obesity and morbid obesity

Akesis files pre-IND for AKP-020

Noven to acquire JDS Pharmaceuticals

Pieris validates pulmonary delivery of Anticalin candidate

AnGes updates phase II study of NF-kappaB decoy oligodeoxynucleotide

Data on apixaban safety and antithrombotic activity accumulate

Ixabepilone demonstrates activity in phase II metastatic breast cancer studies

DUET studies show efficacy of TMC-125 in previously treated HIV patients

Daichii Sankyo profiles novel FXa inhibitor

Novel cholesteryl ester transfer protein inhibitors reported by Lilly

Recent patents describe new agents targeting cardiovascular diseases

FGF-1 approved for phase II trial in coronary heart disease

Protox reports positive data from PRX-302 phase I clinical trial in prostate cancer

Novel cathepsin C inhibitors presented at the AFMC meeting

Genaera grants option to license pexiganan to MacroChem

Positive results for Theravance's TD-1792 for treatment of cSSSI

Depomed reports results of Gabapentin GR phase III trial

Carbaglu granted fast track designation for NAGS deficiency

sNDA planned for Tygacil in community-acquired pneumonia

Recent patents report novel therapeutic agents for dermatological disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...